Results 181 to 190 of about 60,957 (246)

Selumetinib as an Effective Therapy of Histiocytic Sarcoma Evolving From a B‐Cell Acute Lymphoblastic Leukaemia

open access: yeseJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Introduction Histiocytic sarcoma (HS) is a rare neoplasm derived from non‐Langerhans histiocytic cells, exceptionally arising from B‐ALL. Methods We present the case of a child with high‐risk B‐ALL with PAX5 P80R mutation. Results Despite initial remission, a chemoresistant paravertebral mass was identified as HS.
Laetitia Largeaud   +12 more
wiley   +1 more source

What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog

open access: yes
Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson   +5 more
wiley   +1 more source

A Combination of Xanthohumol and Ursolic Acid in the Diet Leads to Synergistic Inhibition of Prostate Cancer Progression

open access: yesMolecular Carcinogenesis, Volume 65, Issue 4, Page 508-522, April 2026.
ABSTRACT Prostate cancer (PCa) is the second most common cancer and second leading cause of cancer death for American men. Chemoprevention by using phytochemicals offers a promising approach to improve outcomes due to their ability to act on cancer cell metabolism and growth while maintaining low toxicity profiles.
Rachel Clark   +6 more
wiley   +1 more source

Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T‐Cell Lymphoma With Unusually Long Clinical Course

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 4, Page 340-346, April 2026.
ABSTRACT Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T‐cell lymphoma (PCAECTCL) is a rare and aggressive malignancy, with limited documented cases in pediatric patients. This report presents a unique case of a 9‐year‐old female with PCAECTCL, characterized by widespread erythematous annular lesions that exhibited an indolent clinical ...
Carrie Meng   +6 more
wiley   +1 more source

Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies

open access: yesEuropean Journal of Haematology, Volume 116, Issue 4, Page 357-367, April 2026.
ABSTRACT PD‐1 inhibitors have reshaped the treatment landscape of classical Hodgkin lymphoma, yet a substantial proportion of patients exhibit primary or acquired resistance driven by tumor‐intrinsic alterations, immunosuppressive microenvironmental signals, metabolic constraints, and EBV‐mediated modulation.
Santino Caserta   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy